Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (751-760 of 869) with videos related to

Pageof 87
Sort By:
Blood Advances|November 8, 2019
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myelomaAndrea Schmidts, Maria Ormhøj, Bryan D Choi, et al.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Blood|October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuYu-Tzu Tai, Myles Dillon, Weihua Song, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: multiple myelomaKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Blood|October 18, 2012
Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort ConsortiumBrenda M Birmann, Marian L Neuhouser, Bernard Rosner, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
The Journal of Clinical Investigation|January 26, 2008
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceSiddhartha Mukherjee, Noopur Raje, Jesse A Schoonmaker, et al.
Blood|January 19, 2017
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaMariateresa Fulciniti, Joaquin Martinez-Lopez, William Senapedis, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple MyelomaJohannes M Waldschmidt, Jake A Kloeber, Praveen Anand, et al.
Pageof 87

Showing results (751-760 of 869) with videos related to

Sort By:
Pageof 87
Blood Advances|November 8, 2019
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myelomaAndrea Schmidts, Maria Ormhøj, Bryan D Choi, et al.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Blood|October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuYu-Tzu Tai, Myles Dillon, Weihua Song, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: multiple myelomaKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Blood|October 18, 2012
Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort ConsortiumBrenda M Birmann, Marian L Neuhouser, Bernard Rosner, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
The Journal of Clinical Investigation|January 26, 2008
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceSiddhartha Mukherjee, Noopur Raje, Jesse A Schoonmaker, et al.
Blood|January 19, 2017
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaMariateresa Fulciniti, Joaquin Martinez-Lopez, William Senapedis, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple MyelomaJohannes M Waldschmidt, Jake A Kloeber, Praveen Anand, et al.
Pageof 87